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Abstract
Background: Anogenital warts (AGW) are caused by the most common sexually transmitted infection, human
papillomavirus. The objective of this study was to examine AGW incidence from 1990 to 2011 by sex, age, income
quintile, and residential area category (urban/rural). The study period included the initiation of school-based HPV
vaccination for girls in the sixth grade, which began in 2008. The data presented in this paper may also be useful
for establishing baseline rates of AGW incidence which may be used to evaluate the success of the school-based
HPV immunization program.
Methods: Cases of anogenital warts were identified using Manitoba’s administrative databases of Physician Claims
and Hospital Discharge Abstracts. Annual age-standardized incidence in Manitoba from 1990 to 2011 was calculated.
Incident AGW rates were compared by sex, age group, residential area category (urban/rural), and household income
quintile using logistic regression. Joinpoint regression analyses were used to evaluate the time trends of AGW.
Results: Prior to 2000, AGW incidence was higher among females than males. However, from 2000 to 2011 the
incidence was higher among males and increased steadily over time. AGW incidence tended to peak in younger
age groups among females compared to males. Females and males living in urban areas had nearly twice the
odds of AGW occurrence compared to those in rural areas.
Conclusions: There is a need for education about AGW in male population. The upcoming initiation of HPV
vaccination among boys may reduce the incidence and should be evaluated.
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Key messages
 Anogenital warts incidence was higher among
females prior to 2000, but since then has been
higher among males than females and has increased
steadily.
 AGW incidence was higher among males at all age
groups except 15–19; by age 25 the incidence was
1.5 to 2 times higher than females.
 Both females and males living in urban areas had
twice the odds of AGW occurrence compared to
those in rural areas.
Background
Anogenital warts (AGW) are caused by the most com-
mon sexually transmitted infection, human papillomavi-
rus (HPV) [1]. Asymptomatic cervical HPV infection
may be detected among 5 % to 40 % of females of repro-
ductive age [2]. Over time, an individual may be infected
with different HPV subtypes and may clear some HPV
infections naturally [1, 2]. It is estimated that 90 % of
AGW are caused by HPV type 6 and HPV type 11 [3, 4].
AGW may be visible as single or multiple flesh-
coloured bumps in the anogenital region. Whether
treated or not, AGW are highly infectious and recurrent
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[5] and are associated with relatively high treatment
costs. A study of the costs associated with AGW in British
Columbia from 1998 to 2006 found that on average the
treatment of one episode of AGW cost $176 for males
and $207 for females [6]. A recent review based on 32 arti-
cles published globally on the topic of AGW incidence
from 2001 to 2012 found that the incidence of AGW
ranged from 160 to 289 per 100,000, and peaked before
the age of 24 among females and between 25 and 29 years
of age among males [7]. Only one other article described
AGW incidence in Manitoba, and it included data up to
2004 [8]. In the year that AGW incidence was last re-
ported, 2004, the incidence of AGW among females was
120 cases per 100,000 persons and among males it was
154 cases per 100,000 persons. From 1985 to 1999, the in-
cidence of AGW in Manitoba was higher among females
than males, and showed a downward trend for both from
1992 to 1999 [8]. The incidence in almost all age groups
continued to increase among males but decreased among
females from 2000 to 2004, and beginning in the year
2000 the incidence has been higher among males than
females [8]. It is not known whether the increasing
trend of AGW in men will continue. It is also lack in-
formation on the characteristics of this increasing trend
of AGW in men.
An HPV vaccine (Gardasil), which provides protection
against HPV types 6, 11, 16, and 18, has been available
free-of-charge to all females in Grade 6 in Manitoba
since September 2008. Since November 2012, all females
between 9 and 26 years of age with an increased risk of
HPV infection (determined by a health care provider)
are also eligible to receive the HPV vaccine [9]. Starting
in September 2016, the Manitoba government will fur-
ther expand the HPV vaccination program to include
males in Grade 6 or born on or after January 1st 2005
[10]. Population-based baseline data of the incidence of
AGWs in females and males is useful for the evaluation
of the success of these vaccination initiatives.
The objective of this study was to examine AGW inci-
dence from 1990 to 2011 by sex, age, income quintile,
and residential area category (urban/rural), determining
whether the increase in AGW rate among males de-
tected in 2004 continued. The study period included the
initiation of school-based HPV vaccination for girls
(which began in 2008) and but not boys (which will
begin in 2016) in the sixth grade. The data presented in
this paper will be useful for establishing baseline rates of
AGW incidence which may be used to evaluate the suc-
cess of the school-based HPV immunization program.
Methods
Data sources
Annual age-standardized incidence of AGW in Manitoba
from 1990 to 2011 was calculated by sex, age group,
income quintiles, and geographic residential area (urban
or rural). The two major cities in Manitoba are Winnipeg,
Manitoba’s biggest urban centre (estimated population
672,000) and Brandon (estimated population 46,000 popu-
lation) [11]. These two cities are grouped as the “urban”
residential category and include 60 % of Manitoba’s
population. The rest of Manitoba is the “rural” resi-
dential category.
Data was obtained from the centralized Manitoba
Health, Healthy Living and Seniors databases, including:
the Manitoba Population Registry, Physician Claims, and
Hospital Discharge Abstracts. The Manitoba Population
Registry was used to identify all Manitobans who were
eligible for provincial health insurance benefits. Physician
Claims (including shadow billing) and Hospital Discharge
Abstracts were used to identify cases of AGW. Specific-
ally, the de-identified, individual, line-level data from
physician and hospital claims (which captured AGW cases
diagnosed and treated in Manitoba) were utilized. Shadow
billings are claims submitted to the provincial govern-
ment, by physicians who are not fee-for-service, for
administrative purposes only (i.e. as a record of ser-
vices provided).
Manitoba population data for June 30th of each year
were provided by the Health Information Management
Branch of Manitoba Health, Healthy Living and Seniors.
Standard protocol approvals, registrations, and patient
consents
The University of Manitoba Health Research Ethics
Board approved the study. As a public health surveillance
activity, a notification by the Manitoba Health Information
Privacy Committee for analyzing administrative data was
obtained. This study involved the use of anonymous pro-
vincial health insurance administrative data and did not
involve any direct patient contact. Consent from patients
was not required.
Case definition
AGW cases were identified based on the procedure
codes specific to condyloma (Additional file 1: Table S1
and Table S4, S5) from the medical claims data. The con-
dyloma procedure codes are analogous to the Current
Procedure Terminology codes used in the United States.
The diagnosis and procedure codes, International Clas-
sification of Diseases [(ICD), Ninth Revision and 10th
Revision (ICD 9/10)] recorded in the hospital records
were used to identify the AGW cases in hospital settings
(Additional file 1: Table S2 and Table S3). Each incident
AGW occurrence (case) was defined as one “episode of
care” to distinguish it from subsequent occurrences (see
below). AGW-specific condyloma tariff (physician billing)
and procedure (Hospital Discharge Abstracts) codes listed
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in two administrative databases from 1990 to 2011 were
used to identify AGW cases.
For those AGW that were treated during a hospital
stay and did not generate a record in the physician
claims database, a combination of ICD (9/10) diagnosis
codes and procedure codes were used to identify the
AGW cases.
The case definition used in this study is consistent
with the case definition used for previous studies of
AGW [8].
Episode of care of anogenital warts and incident anogenital
warts cases
An “episode of care” includes all AGW diagnoses and
AGW-related billing which occurred within a twelve
month period of time. If another AGW claim occurred
more than twelve months after a previous AGW episode
of care, it was considered a new AGW episode (i.e. a
new AGW case).
Episodes of care were identified using the hospital and
physician claims databases. If any of the below occurred
more than twelve months after a previous AGW episode
of care, it is considered a new AGW episode:
a. an AGW-related tariff code, OR
b. an AGW ICD-9/10 code, OR
c. an AGW-related procedure code followed by
another claim within two weeks that had an AGW-
related ICD code (ICD9 = 078, Other disease due to
viruses and Chlamydia).
If any of the above occurred within twelve months of a
previous episode of care, then it is considered as part of
the same AGW episode of care.
The diagnostic date for a new AGW case was defined
as the earliest date listed in hospital or physician claims
for that particular episode of care. If a person died or
moved out of province within the twelve month period
of the AGW episode of care, the coverage cancellation
date, recorded in the Manitoba Population Registry, was
used as the end of that episode of care.
Statistical analysis
Age-standardized incidence was calculated using inci-
dent cases as the numerator and mid-year age-specific
populations as the denominator. All incidence rates are
reported as cases per 100,000 persons in the Manitoba
population. Ninety-five percent confidence intervals
(95 % CI) of rates were calculated, and formal statistical
testing for incidence rate ratios was undertaken using
Poisson regression, with the natural log of the popula-
tion as an offset variable. As personal income data is not
available in the administrative database, we linked the
median household income at the neighbourhood-level
(forward sortation area; ie. first 3 digits of postal code)
from Canadian Census data in 2001 to the residential
area of patients recorded in the databases as a proxy for
socioeconomic status [12–14]. Median household in-
come was grouped into quintiles, less than CAD $17,414
as the lowest quintile (Q1), CAD$17,415–20,411 as sec-
ond quintile (Q2), CAD$20,412–24,422 as the third
quintile (Q3), CAD$24,423–27,848 as the fourth quintile
(Q4), and CAD$27,845–35,122 as the highest quintile
(Q5). Based on the residential postal codes, data were
grouped as rural or urban category. The two major
urban centers (Winnipeg and Brandon) were categorized
as urban and the rest of the province was categorized as
rural. Cases with a missing or unknown postal code or
originating from out of province were excluded from
the region-specific analyses. Household income quintile
categories were obtained by linking the forward sorta-
tion area code (first three digits of the postal code) to
Canadian census data [15].
Incident AGW rates were compared by sex, age group
(0–14, 15–19, 20–24, 25–29, 30–39, 40–49, 50–59, and
60+ years), residential area category (urban versus rural),
five-year period, household income quintile using logis-
tic regression. Results of regression models are summa-
rized as adjusted odds ratios with 95 % confidence
intervals (CI). These analyses were conducted using SAS
v9.4 (SAS Institute, Cary, NC).
Historical cohort analyses were performed to assess
the rates and time trends of AGW in females and males.
Joinpoint regression analyses [16–18], developed by
SEER (Surveillance Epidemiology and End Results, Na-
tional Cancer Institute, United States), were used to evalu-
ate the changes in time trends of AGW in females and
males, and further by urban and rural residential areas.
This study was approved by the Health Research Ethics
Board at University of Manitoba.
Results
Overall time trends of anogenital warts incidence in
Manitoba
There were 31,510 AGW cases identifiable in the admin-
istrative databases in Manitoba from 1990 to 2011;
15,208 among females and 16,302 among males. The
age-standardized incidence of AGW was higher among
females compared to males until 1999 (Fig. 1). However,
this trend has reversed since 2000 with AGW incidence
higher among males than females. Among males, the
age-standardized AGW incidence increased 31 % from
124 (95 % CI 114–134) cases per 100,000 persons in
2001 to 175 (95 % CI 164–187) cases per 100,000 per-
sons in 2010 (Fig. 1). Consequently, the male to female
incidence rate ratio steadily increased from 1.05 (95 %
CI 0.94–1.18) in 2001 to 1.50 (95 % CI 1.35–1.65) in
2010 and 1.39 (95 % CI 1.26–1.54) in 2011. Time trend
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analysis revealed two distinctive time periods and chan-
ging rates of AGW in males and females, respectively. The
average annual change in AGW incidence was–3.35 %
among females from 1990 to 2000 (p < 0.001), and inci-
dence did not change from 2000 to 2011 (annual percent
change 0.79, p = 0.09). The average annual change of
AGW incidence in males was −1.86 % from 1990 to 1998
(p = 0.016), and 2.80 % from 1998 to 2011 (p < 0.001).
Compared to the earliest time period (1990–1994), the
odds of AGW occurrence among females were consist-
ently low (between 0.75 and 0.83) after adjusting for age
group, geographic residential area category, and income
quintile (Table 1). Starting in 2005, males had a greater
odds of AGW compared to the time period 1990–1994.
Incidence of anogenital warts by Age group and Sex in
Manitoba
Among females, the incidence of AGW has been con-
sistently higher among those aged 15–19, 20–24, and
25–29 years while among males it has been consistently
highest in the 20–24, 25–29, and 30–39 age groups
(Fig. 2). The highest incidence of AGW occurred among
those aged 20–24 in both males and females (Table 1
and Fig. 2). As illustrated in Fig. 2, AGW incidence was
highest among females aged 15–19 and 20–24 and males
aged 20–24 during the period of 1990 to 1994 and
among females in this age group the incidence has been
substantially lower since then. Among males in this age
group, the same high incidence was reached again in
2005–2011.
Urban effects on the incidence of anogenital warts
AGW incidence was higher in urban areas for both
females and males (Fig. 3). The trend lines of AGW inci-
dence were parallel for urban and rural for both females
and males. After adjusting for age group, 5-year time pe-
riods, and income quintile, both urban females and males
had an almost 2-fold greater odds of AGW compared to
their counterparts living in rural areas (Table 1). Multi-
variable logistic regression analysis for the time periods
of 1990–1999 and 2000–2011 separately revealed two
trend changes for males and females. From 1990 to
1999, males had 20 % lower odds of AGW than females
(OR = 0.80, 95 % CI 0.75–0.86). However, from 2000 to
2011, males had 7 % greater odds of AGW infection
(OR = 1.07, 95 % CI 1.01–1.14) after adjusting for the
interaction of residential area and age.
A substantial increasing trend of AGW incidence oc-
curred among both urban and rural males after 1998
(Fig. 3). However, AGW rates in urban and rural females
showed a steady downward trend since 1990, at an aver-
age downward change of 3.35 % (p < 0.001) per year, and
stabilized from 2000 to 2011.
Discussion
This study provided population-based descriptive epide-
miologic information about AGW in Manitoba from
1990 to 2011. The incidence was found to be higher
among females than males prior to 2000, which is con-
sistent with previously published data [8]. Since 2000,
the incidence of AGW has been higher among males
than females and has increased steadily, with the inci-
dence among females remaining steady and therefore
the gap in incidence between females and males widen-
ing over time. Consequently, the male to female inci-
dence rate ratio also steadily increased as the incidence
of AGW among males grew to 50 % higher than females
by 2010. A similar pattern of increasing AGW incidence
among males was observed in Quebec, where it in-
creased from 83 per 100,000 in 1998 to 103 per 100,000
in 2007 [19]. This is consistent with the sex-specific re-
sults of 32 studies conducted globally during the period
of 2001 to 2012, whereby the median incidence among
males (137 per 100,000 per year) was indeed higher than
Fig. 1 Age-Standardized Incidence (per 100,000 persons) of AGW in Manitoba, 1990 – 2011
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that among females (120.5 per 100,000 per year) [7]. The
changing sex ratio in sexually transmitted diseases has
been suggested as a surrogate marker of changes in sex-
ual behaviors among men who have sex with men
(MSM) [20]. The rising trends of AGW in males is con-
current with the increasing trends of gonorrhea and
syphilis in males in Canada [21]. The resurging syphilis
in males is largely attributed to the high-risk sexual
practices among some MSM, such as using club drugs,
multiple sexual partners, and larger sexual networks
formed using the internet [22–27]. Therefore, changes in
the sexual practices among MSM may also be an under-
lying factor for the rising AGW incidence among males
in Manitoba. However, because sexual behavior and sexual
orientation data are not available in the health insurance
administrative databases, this study cannot assess the
Fig. 2 Sex Stratified Age-Specific 5-year Average AGW Incidence (per 100,000 persons) in Manitoba, 1990 – 2011
Table 1 Associations of AGW Incidence (per 100,000) and Demographic Factors in Manitoba, 1990–2011
Effect Female and male combined Female Male
Incidence (95 % CI) Odds ratio (95 % CI) Incidence (95 % CI) Odds ratio (95 % CI) Incidence (95 % CI) Odds ratio (95 % CI)
All 123 (122–125)
Female 117 (115–119) Ref 117 (115–119)
Male 129 (127–131) 1.08 (1.05–1.10)* 129 (127–131)
Age 0–14 10 (9–11) 0.02 (0.02–0.02)* 9 (8–11) 0.02 (0.02–0.02)* 10 (9–12) 0.02 (0.02–0.03)*
Age 15–19 212 (205–218) 0.46 (0.44–0.48)* 326 (314–338) 0.65 (0.62–0.69)* 103 (96–109) 0.24 (0.23–0.26)*
Age 20–24 480 (470–490) Ref 520 (505–536) Ref 440 (426–453) Ref
Age 25–29 337 (329–346) 0.69 (0.67–0.71)* 271 (261–282) 0.51 (0.49–0.54)* 403 (390–416) 0.90 (0.86–0.94)*
Age 30–39 177 (173–181) 0.37 (0.35–0.38)* 136 (131–141) 0.26 (0.25–0.27) 218 (211–225) 0.49 (0.47–0.51)*
Age 40–49 93 (90–96) 0.19 (0.19–0.20)* 79 (75–83) 0.15 (0.14–0.16)* 106 (102–111) 0.24 (0.23–0.25)*
Age 50–59 53 (50–55) 0.11 (0.10–0.12)* 46 (43–50) 0.09 (0.08–0.10)* 59 (55–63) 0.13 (0.12–0.14)*
Age 60+ 22 (21–23) 0.05 (0.04–0.05)* 15 (14–17) 0.03 (0.03–0.03)* 30 (28–33) 0.07 (0.06–0.08)*
1990–1994 140 (137–144) Ref 146 (142–151) Ref 134 (130–139) Ref
1995–1999 114 (111–117) 0.86 (0.83–0.89)* 115 (111–119) 0.83 (0.79–0.87)* 113 (109–117) 0.89 (0.85–0.93)*
2000–2004 112 (109–114) 0.86 (0.84–0.89)* 102 (98–105) 0.75 (0.72–0.79)* 122 (118–126) 0.99 (0.95–1.04)
2005–2009 125 (122–128) 0.97 (0.94–1.00) 112 (109–116) 0.83 (0.79–0.86)* 138 (134–142) 1.14 (1.09–1.19)*
2010–2011 128 (123–132) 0.99 (0.95–1.03) 105 (99–111) 0.77 (0.72–0.82)* 151 (144–158) 1.24 (1.17–1.31)*
Rural 74 (72–75) Ref 75 (73–77) Ref 73 (70–75) Ref
Urban 155 (153–157) 1.84 (1.79–1.90)* 143 (141–146) 1.75 (1.67–1.83)* 167 (164–170) 1.93 (1.85–2.01)*
Income quintile 1 83 (81–85) Ref 84 (81–87) Ref 82 (79–86) Ref
Income quintile 2 113 (110–115) 1.20 (1.15–1.24)* 107 (103–110) 1.16 (1.10–1.22)* 118 (114–122) 1.24 (1.18–1.31)*
Income quintile 3 139 (136–142) 1.15 (1.10–1.19)* 133 (129–137) 1.13 (1.07–1.20)* 146 (142–150) 1.17 (1.11–1.24)*
Income quintile 4 166 (162–170) 1.38 (1.32–1.43)* 153 (147–158) 1.32 (1.24–1.40)* 179 (173–186) 1.45 (1.37–1.54)*
Income quintile 5 139 (134–144) 1.14 (1.09–1.20)* 124 (118–131) 1.07 (1.00–1.15)* 154 (147–162) 1.24 (1.16–1.33)*
Note: *p<0.0001
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possible relationship between rising AGW incidence and
trends in sexual behaviours.
AGW incidence tended to peak in younger age groups
among females compared to males. The male to female
incidence ratio indicated an often much higher incidence
among males at all age groups except 15–19, where the
incidence among males was only 40 % that of females.
However, by the age of 25 the incidence of AGW among
males was one-and-a-half to two times the incidence
among females. These results are consistent with a re-
view of 32 articles published globally on the topic of
AGW incidence from 2001 to 2012, which found that
the incidence of AGW peaked before the age of 24
among females and between 25 and 29 years of age
among males [7.] However, the incidence observed in
Manitoba over this time period among those aged 20–24
(520 and 440 cases per 100,000 among females and
males, respectively) was notably higher than that observed
elsewhere in Canada for the same age group, which
ranged from 338 to 342 per 100,000 among females and
270 to 300 among males in BC and Quebec, respectively,
for a similar time period [6, 28].
Both females and males living in urban areas had al-
most twice the odds of AGW occurrence compared to
those in rural areas. The same temporal trend in which
the incidence among males exceeded that of females and
increased over time beginning in 2000 was observed in
both urban and rural areas. The higher incidence of
AGW in urban areas compared to rural areas may relate
to greater MSM populations in urban areas [29] and dif-
ferences in sexual mixing patterns, which are known to
be associated with HIV, gonorrhea, and chlamydia risk
[30–32]. It has been reported that for HPV type 6 and
HPV type 11, which are most commonly associated with
AGW, the prevalence among men who have sex with
men (MSM) was very high (39.2–53.2 %) [33]. The
higher AGW incidence and increasing trend that we ob-
served among urban males could be partially related to
high risk sexual behaviours in urban MSM populations
[33]. It is also possible that individuals in urban areas
are more likely to seek healthcare for AGW, and there-
fore were identifiable as AGW cases using the provincial
administrative databases. Similar to our results, a study
of AGW incidence in Germany from 2005–2006 re-
vealed a higher incidence in urban areas compared to
other regions [34]. To our knowledge these are the only
reports of an observed urban–rural divide in AGW inci-
dence. Further research is needed to elucidate possible
explanations for the observed urban–rural differences in
AGW incidence.
An online survey conducted across Canada in 2011
found that on average only half of the respondents be-
lieve AGW to be a serious STI, only one-quarter knew
that it is associated with HPV, and 57 % were either not
sure whether a condom would prevent transmission or
believed that it would [28]. Other studies have indicated
not only a lack of perceived risk for AGW among men
who have sex with men in North America but also a lack
of knowledge about the etiologic cause of AGW and the
link between HPV infection and anal cancer [35, 36].
However, once informed of the role of HPV, hypothetical
acceptance of HPV vaccine was common [35, 36]. HPV
has been framed as a female problem, with emphasis on
its etiologic role in cervical cancer and the targeting of
vaccination programs towards females. This may par-
tially explain the lack of awareness and increasing inci-
dence among males since 2000. Education about HPV,
its prevention, and the diseases it may cause are needed
among both female and male populations. It has been
recommended that HPV vaccination for boys could be an
effective and cost-saving strategy for oropharyngeal cancer
[37] and AGW [38]. An upcoming HPV immunization
program among boys in Grade 6 in Manitoba will offer an
important approach to reducing the high incidence of
AGW among males. Research of the cost-effectiveness of
the HPV vaccine in Manitoba and an evaluation of the ac-
ceptability and effectiveness of the Grade 6 vaccination
program in reducing AGW incidence would provide use-
ful information for programs.
The data presented in this report is subject to a num-
ber of limitations. It likely underestimates the actual oc-
currence of AGW in Manitoba as it relies on diagnosed
cases and does not include those cases for which treat-
ment was not sought. Further, incomplete shadow billing
by physicians who are not fee-for-service and the exclu-
sion of emergency department data may also result in an
underestimate. The data included in this study were ob-
tained from existing administrative databases compiled
for other purposes and subject to the coding practices
used over time. Although the accuracy of ICD codes and
completeness of the diagnoses captured in hospital
discharge records have been questioned [39, 40], the
Fig. 3 The Trends of Age-Standardized Incidence (per 100,000
persons) of AGW by Sex and Geographic Residential Area in
Manitoba, 1990 - 2011
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overall quality of the administrative databases has been
demonstrated [41, 42]. Cases were based on clinical obser-
vations and not confirmed by laboratory results, though
AGW clinical diagnoses have been found to correlate well
with histological results [43].
Strengths of this population-based study include the
fact that it is free from selection bias and the limitations
of self-report data. Results of this study are generalizable
to other similar populations with a similar medical
system.
Conclusions
Since 2000 the incidence of AGW among males in
Manitoba has been increasing and is particularly high
among those residing in urban areas. This observation is
consistent with the increasing incidence of syphilis and
gonorrhea among males in Manitoba and may be related
to increasing sexual risk behaviours among some urban
MSM populations. Lower AGW rates in rural males may
be related to lower risk behaviours or healthcare seeking
behavior if fewer seek healthcare, resulting in a smaller
proportion of AGW cases being diagnosed compared to
their urban counterparts. Moreover, HPV has been
framed largely as a female problem, which may partially
explain the lack of awareness and increasing incidence
among males. More sexual health education may help
patients overcome the stigma of early diagnosis of sexu-
ally transmitted infections and improve sexual health in
general. There is a need for education about HPV, its
prevention, and the diseases it may cause among both
female and male populations. Also, effectiveness studies
of the HPV vaccination program among Grade 6 males
in Manitoba, to begin in 2016, will generate useful evi-
dence about the importance of targeting prevention ac-
tivities towards males.
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